AlMarzoug Alanoud, AlOrainy May, AlTawil Lama, AlHayaza Ghada, AlAnazi Rasha, AlIssa Ahmed, AlSheikh Afaf, AlKhalifah Abdullah, AlHarithy Ruaa
Department of Dermatology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Department of Dermatology, Security Forces Hospital, Riyadh, Saudi Arabia.
Int J Dermatol. 2022 Jul;61(7):886-894. doi: 10.1111/ijd.15917. Epub 2021 Oct 29.
Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss that can involve the scalp, face, and body. Severe AA subtypes have a poorer prognosis and can be challenging to treat. Tofacitinib, a recently introduced Janus kinase inhibitor, has shown positive results in treating AA. This multicenter study demonstrates the efficacy of tofacitinib and the patient response rate in a Saudi population. It also highlights patient characteristics that may serve as predictors of the therapeutic response to tofacitinib.
A prospective cohort study design was utilized. Study participants were included from three medical centers in Riyadh, Saudi Arabia. The Severity of Alopecia Tool (SALT) score was used to assess the percentage of hair loss at baseline and the percentage of hair regrowth at 3 and 6 months.
The sample size was 68 with an average baseline SALT score of 76.8 ± 27.6%. Data at 6 months were available for 45 patients. Of these, 62.2% achieved a SALT score of >50%. Patients with a score of <50% had a significantly higher baseline SALT score compared to patients with >50% score. The past use of systemic steroids was associated with a diminished response to therapy (P = 0.015). The response to therapy was significantly higher in patients with AA compared to alopecia totalis and alopecia universalis.
Tofacitinib is an effective and well-tolerated treatment for severe AA and exhibits a good safety profile.
斑秃（AA）是一种自身免疫性疾病，其特征为非瘢痕性脱发，可累及头皮、面部和身体。严重的AA亚型预后较差，治疗具有挑战性。托法替布是一种最近引入的 Janus 激酶抑制剂，在治疗 AA 方面已显示出积极效果。这项多中心研究证明了托法替布在沙特人群中的疗效和患者反应率。它还突出了可能作为托法替布治疗反应预测指标的患者特征。
采用前瞻性队列研究设计。研究参与者来自沙特阿拉伯利雅得的三个医疗中心。使用脱发严重程度工具（SALT）评分来评估基线时的脱发百分比以及3个月和6个月时的毛发再生百分比。
样本量为68，平均基线SALT评分为76.8±27.6%。45名患者有6个月的数据。其中，62.2%的患者SALT评分>50%。评分<50%的患者与评分>50%的患者相比，基线SALT评分显著更高。既往使用全身类固醇与治疗反应降低相关（P = 0.015）。与全秃和普秃患者相比，AA患者的治疗反应显著更高。
托法替布是治疗重度AA的一种有效且耐受性良好的治疗方法，并且具有良好的安全性。
